Background Modelling studies have been widely used to inform human papillomavirus
(HPV) vaccination policy decisions; however, many models exist and it is not known whether …

Human papillomavirus (HPV) is the necessary cause of cervical cancer, the fourth most
common cancer and cause of cancer-related death in females worldwide. HPV also causes …

Human papillomavirus (HPV)-related screening technologies and HPV vaccination offer
enormous potential for cancer prevention, notably prevention of cervical cancer. The …

The persisting burden of cervical cancer in underserved populations and low-resource
regions worldwide, worsened by the onset of the COVID-19 pandemic, requires proactive …

Cancer burden worldwide is projected to rise from 14 million new cases in 2012 to 24 million
in 2035. Although the greatest increases will be in developing countries, where cancer …

Conclusion The incidence of penile cancer is higher in developing countries as compared
with developed countries; however, there is a significant variation among ethnic groups. This …

Objective To assess the reduction in the vaccine preventable burden of cancer in men if
boys are vaccinated along with girls against oncogenic human papillomavirus (HPV) …

ABSTRACT Introduction: Cost-effectiveness thresholds (CETs) are used to judge if an
intervention represents sufficient value for money to merit adoption in healthcare systems …

Objective To provide family physicians with information on the efficacy, safety, public health
effects, and cost-effectiveness of the 9-valent human papillomavirus (HPV) vaccine. Quality …

Abstract Background The story of Human Papillomavirus vaccination demands reflection not
only for its public health impact on the prophylactic management of HPV disease, but also …